• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

    2/13/24 5:09:39 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email
    SC 13G 1 tv01467-mirumpharmaceuticals.htm SCHEDULE 13G mirumpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Mirum Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  604749101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  604749101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    46,538

    7.  SOLE DISPOSITIVE POWER

    2,397,149

    8.  SHARED DISPOSITIVE POWER

    79,095

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,476,244

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.31%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Mirum Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    950 Tower Lane, Suite 1050
    Foster City, CA 94404

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    604749101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MIRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    5/19/2025$73.00Buy
    H.C. Wainwright
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    9/20/2023$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $MIRM
    Financials

    Live finance-specific insights

    See more
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      - 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

      2/26/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 5:04:31 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/12/25 4:51:20 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/10/25 5:12:58 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

      For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

      2/21/25 11:48:20 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00

      5/19/25 8:53:13 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

      Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

      4/17/24 7:27:53 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously

      12/18/23 11:54:26 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

      - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

      1/13/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GLOBAL CONTROLLER Howe Jolanda sold $107,343 worth of shares (2,415 units at $44.45), decreasing direct ownership by 50% to 2,426 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/19/25 5:40:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GLOBAL CONTROLLER Howe Jolanda exercised 58,215 shares at a strike of $2.67 and sold $2,554,763 worth of shares (57,606 units at $44.35), increasing direct ownership by 14% to 4,841 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND COO Radovich Peter converted options into 14,440 shares and sold $348,364 worth of shares (7,879 units at $44.21), increasing direct ownership by 54% to 18,672 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:07 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednesday, May 21st at 9:00 AM ET. Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. is a biopharmaceutical compan

      5/14/25 4:05:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $44.27 per share, Mirum's closing trading price on May 9, 2025, and will vest over four years, with 25%

      5/9/25 6:00:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/15/25 3:32:46 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/14/25 11:59:51 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.

      10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

      5/7/25 4:08:12 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 4:37:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:55:40 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:25:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care